WO2011150897A3 - Método para la terapia del cáncer - Google Patents

Método para la terapia del cáncer Download PDF

Info

Publication number
WO2011150897A3
WO2011150897A3 PCT/CU2011/000003 CU2011000003W WO2011150897A3 WO 2011150897 A3 WO2011150897 A3 WO 2011150897A3 CU 2011000003 W CU2011000003 W CU 2011000003W WO 2011150897 A3 WO2011150897 A3 WO 2011150897A3
Authority
WO
WIPO (PCT)
Prior art keywords
increase
nuclear localization
cancer therapy
relates
peptide
Prior art date
Application number
PCT/CU2011/000003
Other languages
English (en)
French (fr)
Other versions
WO2011150897A2 (es
Inventor
Maribel GUERRA VALLESPÍ
Julio Raúl FERNÁNDEZ MASSÓ
Alexis Musacchio Lasa
Jeovanis GIL VALDÉS
Osvaldo Reyes Acosta
Brizaida Maylin OLIVA ARGÜELLES
Original Assignee
Centro De Ingeniería Genética Y Biotecnología
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to ES11728172.5T priority Critical patent/ES2619571T3/es
Priority to US13/700,286 priority patent/US8729226B2/en
Priority to RU2012157289/10A priority patent/RU2577993C2/ru
Priority to AU2011260745A priority patent/AU2011260745B2/en
Priority to EP11728172.5A priority patent/EP2578227B1/en
Priority to JP2013512751A priority patent/JP5827322B2/ja
Priority to BR112012030668-5A priority patent/BR112012030668B1/pt
Priority to CN201180026853.7A priority patent/CN102917725B/zh
Application filed by Centro De Ingeniería Genética Y Biotecnología filed Critical Centro De Ingeniería Genética Y Biotecnología
Priority to UAA201215130A priority patent/UA112522C2/uk
Priority to DK11728172.5T priority patent/DK2578227T3/en
Priority to MX2012013923A priority patent/MX2012013923A/es
Priority to KR1020127033777A priority patent/KR101847170B1/ko
Priority to CA2799066A priority patent/CA2799066C/en
Publication of WO2011150897A2 publication Critical patent/WO2011150897A2/es
Publication of WO2011150897A3 publication Critical patent/WO2011150897A3/es
Priority to ZA2012/08905A priority patent/ZA201208905B/en
Priority to US14/075,276 priority patent/US9145554B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)

Abstract

La presente invención describe un método para el tratamiento del cáncer mediante el incremento de la localización nuclear de la proteína COMMD1, lo cual se asocia con la disminución o bloqueo de la proliferación de la célula de cáncer. La invención se relaciona, además, con el uso de agentes que incrementan la localización nuclear de la proteína COMMD1 en la fabricación de un medicamento para la terapia del cáncer. Dichos agentes pueden ser péptidos o proteínas, entre otros compuestos. La invención también se relaciona con la optimización de un péptido, proveniente de la secuencia HARIKPTFRRLKWKKYKGKFW, para incrementar la localización nuclear de la proteína COMMD1 y, de esa forma, aumentar el efecto antitumoral de dicho péptido.
PCT/CU2011/000003 2010-01-25 2011-05-31 Método para la terapia del cáncer WO2011150897A2 (es)

Priority Applications (15)

Application Number Priority Date Filing Date Title
UAA201215130A UA112522C2 (uk) 2010-05-31 2011-05-31 Спосіб терапії злоякісної пухлини
US13/700,286 US8729226B2 (en) 2010-05-31 2011-05-31 Cancer therapy method
DK11728172.5T DK2578227T3 (en) 2010-05-31 2011-05-31 METHOD OF CANCER THERAPY
EP11728172.5A EP2578227B1 (en) 2010-05-31 2011-05-31 Cancer therapy method
JP2013512751A JP5827322B2 (ja) 2010-05-31 2011-05-31 癌の治療方法
BR112012030668-5A BR112012030668B1 (pt) 2010-05-31 2011-05-31 Peptídeos, composição farmacêutica, e combinação farmacêutica
CN201180026853.7A CN102917725B (zh) 2010-05-31 2011-05-31 用于癌症治疗的肽
ES11728172.5T ES2619571T3 (es) 2010-01-25 2011-05-31 Método para la terapia del cáncer
RU2012157289/10A RU2577993C2 (ru) 2010-05-31 2011-05-31 Способ терапии злокачественной опухоли
AU2011260745A AU2011260745B2 (en) 2010-05-31 2011-05-31 Cancer therapy method
MX2012013923A MX2012013923A (es) 2010-05-31 2011-05-31 Metodo para la terapia del cancer.
KR1020127033777A KR101847170B1 (ko) 2010-05-31 2011-05-31 암 치료 방법
CA2799066A CA2799066C (en) 2010-05-31 2011-05-31 Method for cancer therapy
ZA2012/08905A ZA201208905B (en) 2010-05-31 2012-11-26 Cancer therapy method
US14/075,276 US9145554B2 (en) 2010-05-31 2013-11-08 Cancer therapy method

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU2010-113 2010-05-31
CU2010000113A CU23897B1 (es) 2010-05-31 2010-05-31 Péptido para la terapia del cáncer

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US13/700,286 A-371-Of-International US8729226B2 (en) 2010-05-31 2011-05-31 Cancer therapy method
US14/075,276 Division US9145554B2 (en) 2010-05-31 2013-11-08 Cancer therapy method

Publications (2)

Publication Number Publication Date
WO2011150897A2 WO2011150897A2 (es) 2011-12-08
WO2011150897A3 true WO2011150897A3 (es) 2012-03-15

Family

ID=45067129

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CU2011/000003 WO2011150897A2 (es) 2010-01-25 2011-05-31 Método para la terapia del cáncer

Country Status (16)

Country Link
US (2) US8729226B2 (es)
EP (1) EP2578227B1 (es)
JP (1) JP5827322B2 (es)
KR (1) KR101847170B1 (es)
CN (1) CN102917725B (es)
AR (1) AR081259A1 (es)
AU (1) AU2011260745B2 (es)
BR (1) BR112012030668B1 (es)
CA (1) CA2799066C (es)
CU (1) CU23897B1 (es)
DK (1) DK2578227T3 (es)
MX (1) MX2012013923A (es)
RU (1) RU2577993C2 (es)
UA (1) UA112522C2 (es)
WO (1) WO2011150897A2 (es)
ZA (1) ZA201208905B (es)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007095867A1 (es) * 2006-02-24 2007-08-30 Centro De Ingenieria Genetica Y Biotecnologia Peptidos con capacidad anti-tumoral e inmunomoduladora
WO2009021468A1 (es) * 2007-07-31 2009-02-19 Centro De Ingenieria Genetica Y Biotecnologia Péptidos penetradores a células y su uso fusionados a biomoléculas con acción terapéutica

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2105567C1 (ru) * 1995-12-01 1998-02-27 Сергей Юрьевич Родионов Способ лечения злокачественных опухолей

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007095867A1 (es) * 2006-02-24 2007-08-30 Centro De Ingenieria Genetica Y Biotecnologia Peptidos con capacidad anti-tumoral e inmunomoduladora
WO2009021468A1 (es) * 2007-07-31 2009-02-19 Centro De Ingenieria Genetica Y Biotecnologia Péptidos penetradores a células y su uso fusionados a biomoléculas con acción terapéutica

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
D. DAELEMANS: "A synthetic HIV-1 Rev inhibitor interfering with the CRM1-mediated nuclear export", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 99, no. 22, 29 October 2002 (2002-10-29), pages 14440 - 14445, XP055015691, ISSN: 0027-8424, DOI: 10.1073/pnas.212285299 *
HUANG B ET AL: "Posttranslational modifications of NF-kappaB: Another layer of regulation for NF-kappaB signaling pathway", CELLULAR SIGNALLING, ELSEVIER SCIENCE LTD, GB, vol. 22, no. 9, 2 April 2010 (2010-04-02), pages 1282 - 1290, XP027087693, ISSN: 0898-6568, [retrieved on 20100614] *
HUI GENG ET AL: "Phosphorylation of NF-[kappa]B p65 at Ser468 controls its COMMD1-dependent ubiquitination and target gene-specific proteasomal elimination", EMBO REPORTS, vol. 10, no. 4, 1 April 2009 (2009-04-01), pages 381 - 386, XP055015584, ISSN: 1469-221X, DOI: 10.1038/embor.2009.10 *
MARIBEL G. VALLESPI ET AL: "Identification of a novel antitumor peptide based on the screening of an Ala-library derived from the LALF32â??51 region", JOURNAL OF PEPTIDE SCIENCE, vol. 16, no. 1, 1 January 2010 (2010-01-01), pages 40 - 47, XP055015559, ISSN: 1075-2617, DOI: 10.1002/psc.1192 *
MILAID GRANADILLO ET AL: "A novel fusion protein-based vaccine comprising a cell penetrating and immunostimulatory peptide linked to human papillomavirus (HPV) type 16 E7 antigen generates potent immunologic and anti-tumor responses in mice", VACCINE, vol. 29, no. 5, 29 January 2011 (2011-01-29), pages 920 - 930, XP055001692, ISSN: 0264-410X, DOI: 10.1016/j.vaccine.2010.11.083 *
PATRICIA A. J. MULLER ET AL: "Nuclear-Cytosolic Transport of COMMD1 Regulates NF-[kappa]B and HIF-1 Activity", TRAFFIC, vol. 10, no. 5, 1 May 2009 (2009-05-01), pages 514 - 527, XP055015682, ISSN: 1398-9219, DOI: 10.1111/j.1600-0854.2009.00892.x *
SUBASH C. GUPTA ET AL: "Inhibiting NF-[kappa]B activation by small molecules as a therapeutic strategy", BIOCHIMICA ET BIOPHYSICA ACTA (BBA) - GENE REGULATORY MECHANISMS, vol. 1799, no. 10-12, 21 May 2010 (2010-05-21), pages 775 - 787, XP055015585, ISSN: 1874-9399, DOI: 10.1016/j.bbagrm.2010.05.004 *
VAN DE SLUIS BART ET AL: "COMMD1 disrupts HIF-1 alpha/beta dimerization and inhibits human tumor cell invasion", JOURNAL OF CLINICAL INVESTIGATION, vol. 120, no. 6, 10 May 2010 (2010-05-10), pages 2119 - 2130, XP002666589, ISSN: 0021-9738 *

Also Published As

Publication number Publication date
US8729226B2 (en) 2014-05-20
EP2578227B1 (en) 2016-12-28
ZA201208905B (en) 2013-07-31
US20140206621A1 (en) 2014-07-24
AU2011260745A1 (en) 2012-12-06
EP2578227A2 (en) 2013-04-10
MX2012013923A (es) 2013-01-24
CN102917725A (zh) 2013-02-06
CN102917725B (zh) 2014-09-17
RU2577993C2 (ru) 2016-03-20
AU2011260745B2 (en) 2014-08-07
BR112012030668A2 (pt) 2020-08-25
US20130224313A1 (en) 2013-08-29
CA2799066A1 (en) 2011-12-08
CA2799066C (en) 2019-07-23
US9145554B2 (en) 2015-09-29
CU23897B1 (es) 2013-05-31
DK2578227T3 (en) 2017-03-27
RU2012157289A (ru) 2014-07-20
JP2013530162A (ja) 2013-07-25
AR081259A1 (es) 2012-07-18
KR101847170B1 (ko) 2018-05-28
JP5827322B2 (ja) 2015-12-02
BR112012030668B1 (pt) 2022-03-29
WO2011150897A2 (es) 2011-12-08
KR20130089167A (ko) 2013-08-09
CU20100113A7 (es) 2012-06-21
UA112522C2 (uk) 2016-09-26

Similar Documents

Publication Publication Date Title
MX357965B (es) Composicion farmaceutica para el tratamiento y/o prevencion de cancer de vesicula biliar.
AU2018253546A1 (en) Aromatic-cationic peptides and methods for using same
MX358224B (es) Composicion farmaceutica para el tratamiento y/o prevencion de cancer de higado.
PH12018501264A1 (en) Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
NZ630542A (en) Methods of treating a tauopathy
MX360208B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
NZ606195A (en) Methods and compositions for liver cancer therapy
MX360211B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX363136B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
AU2018256498A1 (en) Antibodies to amyloid beta
SG10201908388UA (en) Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
NZ761006A (en) Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema
BR112012024382A2 (pt) agentes que induzem apoptose para o tratamento de câncer e doenças imunes e autoimunesças
MX366130B (es) Inhibidores bivalentes de las proteinas iap y métodos terapéuticos que usan los mismos.
UA107706C2 (en) Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
PH12015500084A1 (en) Rspo3 binding agents and uses thereof
CA3019531A1 (en) Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
UA113712C2 (xx) Антитіло до fap і способи його застосування
MY167232A (en) Polypeptides binding to human complement c5
WO2012068405A3 (en) Modulation of alpha synuclein expression
MY165499A (en) Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
MX2014001489A (es) Composicion para la estimulacion ovarica controlada.
GB2496337A (en) Combination pharmaceutical composition and methods of treating diseases or conditions associated with neurodegenerative diseases
NZ603196A (en) Methods of use of soluble cd24 for therapy of rheumatoid arthritis
IL264382B (en) Compounds for the treatment of blocking myelin regeneration in diseases associated with the expression of the envelope protein herv-w

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201180026853.7

Country of ref document: CN

ENP Entry into the national phase

Ref document number: 2799066

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2013512751

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/A/2012/013923

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2011260745

Country of ref document: AU

Date of ref document: 20110531

Kind code of ref document: A

REEP Request for entry into the european phase

Ref document number: 2011728172

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10507/CHENP/2012

Country of ref document: IN

Ref document number: 2011728172

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 20127033777

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: A201215130

Country of ref document: UA

ENP Entry into the national phase

Ref document number: 2012157289

Country of ref document: RU

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 13700286

Country of ref document: US

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112012030668

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112012030668

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20121130